Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China’s WuXi Pharma Tech Shakes Up Its Board After Tumultuous Year

This article was originally published in The Pink Sheet Daily

Executive Summary

The West's financial morass could ultimately prod the world's pharmaceutical giants to outsource more research and development to lower-cost China, and to WuXi PharmaTech, CEO says.
Advertisement

Related Content

WuXi PharmaTech Lays Off One-fifth Of U.S. Workforce Months After Acquiring American Biologics Firm AppTec
WuXi PharmaTech Lays Off One-fifth Of U.S. Workforce Months After Acquiring American Biologics Firm AppTec
WuXi Reports Expanded Research Deal With J&J And Higher Profits, But Also Sharper Risks Sparked By Global Financial Crisis
Covance, WuXi Abandon Plans To Create Joint Drug Testing Facility In China

Topics

Advertisement
UsernamePublicRestriction

Register

PS068969

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel